HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
12 hedge funds and large institutions have $67.3K invested in HTG Molecular Diagnostics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 0 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
20% more funds holding
Funds holding: 10 → 12 (+2)
2% more capital invested
Capital invested by funds: $66.2K → $67.3K (+$1.07K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.3K |
| 3 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
+$1.91K |
| 4 |
JP Morgan Chase
New York
|
+$34 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$34 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19.8K |
| 2 |
BlackRock
New York
|
-$18.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $39.7K | +$56K | +14,692 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $14K | +$12.3K | +3,223 | +163% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $4K | -$19.8K | -5,208 | -78% |
|
|
4
BlackRock
New York
| $3.48K | -$18.3K | -4,815 | -79% |
|
5
Morgan Stanley
New York
| $2.39K | – | – | – |
|
|
HWM
6
HighMark Wealth Management
St. Paul,
Minnesota
| $1.57K | – | – | – |
|
|
NA
7
Nordwand Advisors
Radnor,
Pennsylvania
| $1.35K | +$1.91K | +500 | New |
|
|
AF
8
Allworth Financial
Folsom,
California
| $754 | +$8 | +2 | +0.7% |
|
|
9
Wells Fargo
San Francisco,
California
| $35 | +$34 | +9 | +225% |
|
|
TWA
10
TCI Wealth Advisors
Tucson,
Arizona
| $6 | – | – | – |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$23 | +6 | +150% |
|
|
12
JP Morgan Chase
New York
| – | +$34 | +9 | +900% |
|
HTGM Hedge Fund Activity: Q1 2023 in Review
12 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q1 2023, worth a combined $67.3K — up 1.6% from $66.2K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HTGM positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $56K. The largest seller was Tower Research Capital (TRC), cutting an estimated $19.8K.
- 12 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q1 2023, up from 10 in Q4 2022.
- Funds reported $67.3K of HTG Molecular Diagnostics, Inc. Common Stock stock for Q1 2023, up 1.6% quarter-over-quarter.
- 2 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q1 2023 and 0 closed out, a net change of +2 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q1 2023 was Vanguard Group, an estimated $56K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q1 2023 was Tower Research Capital (TRC), an estimated $19.8K sold.
Based on aggregated 13F filings for Q1 2023.